STOCK TITAN

Cooper - COO STOCK NEWS

Welcome to our dedicated page for Cooper news (Ticker: COO), a resource for investors and traders seeking the latest updates and insights on Cooper stock.

Overview of CooperCompanies

CooperCompanies (NYSE: COO) is a globally recognized medical device company dedicated to enhancing quality of life through innovative healthcare solutions. Headquartered in San Ramon, California, the company operates through two primary business units: CooperVision and CooperSurgical. With a presence in over 130 countries and a workforce exceeding 15,000 employees, CooperCompanies combines cutting-edge technology with a mission-driven approach to address critical healthcare needs.

CooperVision: Transforming Vision Care

CooperVision is a leader in the contact lens industry, offering a comprehensive portfolio of products designed to improve vision for millions of people worldwide. Its product range includes spherical, multifocal, and toric lenses, as well as specialty lenses crafted from advanced materials like silicone hydrogel. These lenses cater to diverse vision correction needs, such as astigmatism and presbyopia, and are available under well-known brands like Biofinity, MyDay, and Clariti.

What sets CooperVision apart is its commitment to innovation and practitioner support. The company collaborates closely with eye care professionals to deliver tailored solutions that enhance patient outcomes. Its specialty lens portfolio, one of the most extensive globally, underscores its dedication to addressing complex vision challenges. As a key player in the vision care market, CooperVision competes with industry giants like Johnson & Johnson and Alcon, leveraging its expertise and product diversity to maintain a strong market share.

CooperSurgical: Advancing Women’s Health

CooperSurgical focuses on improving healthcare delivery for women by providing a wide array of medical devices and treatment options. Its offerings span fertility treatments, reproductive care, and general women’s health solutions. The company is particularly notable for its comprehensive coverage of the in vitro fertilization (IVF) cycle, making it a trusted partner for fertility clinics worldwide.

Key products include the Paragard hormone-free intrauterine device (IUD), which holds a significant share of the U.S. IUD market, and innovative surgical technologies like the ONETRAC™ portfolio of retractors. CooperSurgical’s dedication to addressing critical healthcare moments for women, babies, and families positions it as a leader in its field.

Global Reach and Market Presence

CooperCompanies has established a robust global footprint, with products sold in over 130 countries. Its dual focus on vision care and women’s health not only diversifies its revenue streams but also mitigates risks associated with market-specific challenges. The company’s strategic acquisitions, such as the integration of obp Surgical, further strengthen its product portfolio and market presence.

Commitment to Innovation and Quality

Innovation is at the core of Cooper’s operations. The company invests heavily in research and development to stay ahead in the competitive medical device landscape. Its focus on high-quality, clinically relevant products ensures that it meets the evolving needs of healthcare providers and patients alike. Additionally, Cooper’s adherence to stringent regulatory standards, including the EU Medical Devices Regulation (MDR), underscores its commitment to safety and compliance.

Challenges and Opportunities

While CooperCompanies enjoys a strong market position, it faces challenges such as regulatory complexities, supply chain disruptions, and intense competition. However, its diversified portfolio and strategic focus on high-growth areas like specialty contact lenses and fertility solutions provide significant opportunities for sustained growth. The company’s ability to integrate acquisitions effectively and innovate continuously will be crucial to its long-term success.

Conclusion

CooperCompanies exemplifies a balanced approach to healthcare innovation, combining a strong product portfolio with a commitment to improving lives. Its leadership in vision care and women’s health, coupled with a global reach and focus on quality, positions it as a key player in the medical device industry. Investors and stakeholders can view Cooper as a company that not only addresses current healthcare needs but is also well-equipped to adapt to future challenges and opportunities.

Rhea-AI Summary
CooperCompanies to participate in Baird Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
conferences
-
Rhea-AI Summary
CooperSurgical's Cord Blood Registry (CBR) will play a key role in the Cord Blood Connect meeting, presenting new scientific data and moderating a forum on the future of cord blood banking. CBR's Newborn Possibilities Program is effective in identifying families likely to use cord blood units for transplants or infusions. Cord blood banks should re-evaluate eligibility criteria. CooperSurgical aims to expand access to more families as the science evolves. Moderating a panel on the future of cord blood banking, CBR will discuss challenges and opportunities in the industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
none
-
Rhea-AI Summary
CooperCompanies announces Q3 2023 financial results with revenue increasing 10% YoY to $930.2 million. CooperVision revenue up 11% to $630.2 million and CooperSurgical revenue up 8% to $300.0 million. GAAP diluted EPS of $1.71, down 14% YoY. Non-GAAP diluted EPS of $3.35, up 5% YoY.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.85%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.24%
Tags
none
-
Rhea-AI Summary
CooperCompanies (NYSE: COO) will release its third-quarter 2023 financial results on August 30, 2023, at 4:15 PM ET, followed by a conference call at 5:00 PM ET to discuss the results and corporate developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
dividends
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.74%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
none

FAQ

What is the current stock price of Cooper (COO)?

The current stock price of Cooper (COO) is $73.77 as of April 4, 2025.

What is the market cap of Cooper (COO)?

The market cap of Cooper (COO) is approximately 14.9B.

What are the main business segments of CooperCompanies?

CooperCompanies operates through two primary segments: CooperVision, focusing on vision care, and CooperSurgical, specializing in women's health and fertility solutions.

How does CooperVision differentiate itself in the contact lens market?

CooperVision offers a diverse range of high-quality lenses, including specialty lenses for complex vision needs, and collaborates closely with eye care professionals.

What products does CooperSurgical offer?

CooperSurgical provides medical devices for fertility treatments, reproductive care, and general women’s health, including hormone-free IUDs and IVF-related technologies.

What challenges does CooperCompanies face?

Cooper faces challenges such as regulatory compliance, market competition, and supply chain disruptions but mitigates risks through diversification and innovation.

In which countries does CooperCompanies operate?

CooperCompanies has a global presence, with products sold in over 130 countries.

What is CooperCompanies’ approach to innovation?

The company invests heavily in R&D to develop high-quality, clinically relevant products and maintains compliance with stringent regulatory standards.

How does CooperCompanies generate revenue?

Revenue is primarily generated through the sale of medical devices in vision care and women’s health, targeting both healthcare providers and end consumers.

What makes CooperSurgical a leader in fertility solutions?

CooperSurgical offers comprehensive IVF cycle coverage and innovative products like the hormone-free Paragard IUD, making it a trusted partner for fertility clinics.
Cooper

NYSE:COO

COO Rankings

COO Stock Data

14.91B
198.75M
0.61%
100.99%
1.54%
Medical Instruments & Supplies
Ophthalmic Goods
Link
United States
SAN RAMON